Additional Information

Description

Sofosbuvir and Velpatasvir are antiviral medications combined in a single tablet, designed to treat chronic hepatitis C virus (HCV) infection in adults. Sofosbuvir is a nucleotide analogue inhibitor of HCV NS5B polymerase, while Velpatasvir is an NS5A inhibitor. Together, they work synergistically to block two key stages of the HCV replication cycle, thereby reducing the virus's ability to replicate and spread in the body.

The combination tablet is typically administered once daily, with or without food, for a treatment duration based on the patient's specific genotype and medical history. This therapy is used in patients with HCV infection who have not previously been treated or have experienced treatment failure with other regimens.

Common side effects of Sofosbuvir and Velpatasvir include fatigue, headache, nausea, and insomnia. Serious side effects are rare but may include liver problems or serious allergic reactions. Patients should be monitored regularly for any signs of adverse effects during treatment.